Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
20 August 2020 | Story Andre Damons | Photo Barend Nagel
Prof Motlalepula Matsabisa, Associate Professor in the Department of Pharmacology at the University of the Free State (UFS), has been appointed as the chairperson of the World Health Organisation’s (WHO) Regional Expert Advisory Committee on Traditional Medicines for COVID-19.

Prof Motlalepula Matsabisa, Associate Professor in the Department of Pharmacology at the University of the Free State (UFS), will lead Africa’s fight against the COVID-19 pandemic with his appointment as chairperson of the World Health Organisation’s (WHO) Regional Expert Advisory Committee on Traditional Medicines for COVID-19.

Prof Matsabisa has been chosen over 25 other experts from 27 African countries to head this expert committee tasked with setting up research and clinical trials for COVID-19 and beyond. The committee is also supported by the African Union (AU), the Centers for Disease Control and Prevention (CDC – Africa), and the European and Developing Countries Clinical Trials Partnership (EDCTP).

This committee was established by the WHO and the Africa CDC on 22 July with the aim of providing independent scientific advice and support to countries on the safety, efficacy, and quality of traditional medicine therapies. It is also an effort to enhance research and development of traditional medicines for COVID-19 in Africa.

Looking forward

“This is a huge continental and global responsibility being laid on my shoulders as a chairperson.  I have to keep the committee together and ensure that it delivers on its set mandate and terms of reference.  I need to ensure that the committee helps the continent and region to get the scientific and legislative aspects on traditional medicine development on track.”  

“I have taken this position and responsibility, knowing quite well what it entails. I want to do this for the continent and for the sake of good science of all traditional healers and consumers of traditional medicines on the continent and beyond,” says Prof Matsabisa.

According to Prof Matsabisa, he is looking forward to working with a team of dedicated experts from 27 countries in the African region, and being of help to countries that need assistance with clinical trials, including preclinical work to move to clinical research.

Prof Matsabisa says he is also looking forward to countries asking South Africa to be part of their multi-centre studies in clinical trials for traditional medicines, and to help set up clinical trial teams that include Western-trained clinicians to get into traditional medicine studies. 

The work of the committee

According to Prof Matsabisa, his new position took effect the same day as his appointment and will run as long as COVID-19 is part of our daily lives and even beyond. It entails supporting member states to implement the WHO master plan for clinical trial protocols in order to generate credible data for COVID-19 results, based on traditional medicines. The committee will also coordinate support to member states in the African region to collaborate on clinical trials of traditional medicine-based therapies – elevating standards by pooling expertise in multicentre studies, as well as complying with GCP and good participatory practice guidelines for trials of emerging and re-emerging pathogens.
“The committee will also advise on strengthening the capacity of national medicine regulatory authorities to accelerate the issuance of marketing authorisations for traditional medicine products that have been well researched for safety, efficacy, and quality, as well as to expedite the approval of clinical trials on traditional medicines. This will help to meet the national registration criteria and the WHO norms and standards of quality, safety, and efficacy for the management of COVID-19 and others.”

“It will also provide independent scientific advice to the WHO and other partners regarding policies, strategies, and plans for integrating traditional medicines into COVID-19 responses and health systems,” explains Prof Matsabisa. 

Aiming for the top spot 

Prof Matsabisa has been described as having the third highest research output – something he is not satisfied with. 
“I was disappointed that only one point separated me from the second place. I will push for first place as this is my ultimate aim. My motivation for this is simple – I like what I am doing, I do not take it as a job but do it because I love research.”  

“I always like to tell students that we should be proud to one day see products in the shops that we can relate to and to which we have contributed or that we have made.   This is what drives me and my staff.  I have a beautiful team of students, staff, and postdoctoral fellows who share my vision of research.  We all have a shared vision and strive to be relevant at all times in science research, development, and teaching.”

• Prof Matsabisa was recently part of a national conference with the theme: Harnessing science, technology, and innovation in response to COVID-19: A national and international effort. The conference was hosted by Dr Blade Nzimande, Minister of Higher Education, Science and Innovation, with Pres Cyril Ramaphosa, Dr Zweli Mkhize, Minister of Health, Ebrahim Patel, Minister of Trade, Industry and Competition, Prof Sarah Anyang Agbor, African Union Commissioner for Human Resources, Science and Technology, and Dr Tedros Adhanom Ghebreyesus, Director-General of the World Health Organisation, in attendance. 

News Archive

Research eradicates bacteria from avocado facility
2017-01-17

 Description: Listeria monocytogenes Tags: Listeria monocytogenes

Listeria monocytogenes as seen under an electron
microscope. The photo was taken with a transmission
electron microscope at the microscopy unit of the UFS.
Bacteriophages (lollipop-like structures) can be seen
next to the bacterial cells.
Photo: Supplied

“The aim of my project was to identify and characterise the contamination problem in an avocado-processing facility and then to find a solution,” said Dr Amy Strydom, postdoctoral fellow in the Department of Microbial Biochemical and Food Biotechnology at the University of the Free State (UFS).

Her PhD, “Control of Listeria monocytogenes in an Avocado-processing Facility”, aimed to identify and characterise the contamination problem in a facility where avocados were processed into guacamole. Dr Strydom completed her MSc in food science in 2009 at Stellenbosch University and this was the catalyst for her starting her PhD in microbiology in 2012 at the UFS. The research was conducted over a period of four years and she graduated in 2016. The research project was funded by the National Research Foundation.

The opportunity to work closely with the food industry further motivated Dr Strydom to conduct her research. The research has made a significant contribution to a food producer (avocado facility) that will sell products that are not contaminated with any pathogens. The public will then buy food that is safe for human consumption.


What is Listeria monocytogenes?

Listeria monocytogenes is a food-borne pathogenic bacterium. When a food product is contaminated with L. monocytogenes, it will not be altered in ways that are obvious to the consumer, such as taste and smell. When ingested, however, it can cause a wide range of illnesses in people with impaired immune systems. “Risk groups include newborn babies, the elderly, and people suffering from diseases that weaken their immune systems,” Dr Strydom said. The processing adjustments based on her findings resulted in decreased numbers of Listeria in the facility.

The bacteria can also survive and grow at refrigeration temperatures, making them dangerous food pathogens, organisms which can cause illnesses [in humans]. Dr Strydom worked closely with the facility and developed an in-house monitoring system by means of which the facility could test their products and the processing environment. She also evaluated bacteriophages as a biological control agent in the processing facility. Bacteriophages are viruses that can only infect specific strains of bacteria. Despite bacteriophage products specifically intended for the use of controlling L. monocytogenes being commercially available in the food industry, Dr Strydom found that only 26% of the L. monocytogenes population in the facility was destroyed by the ListexP100TM product. “I concluded that the genetic diversity of the bacteria in the facility was too high and that the bacteriophages could not be used as a control measure. However, there is much we do not understand about bacteriophages, and with a few adjustments, we might be able to use them in the food industry.”

Microbiological and molecular characterisation of L. monocytogenes

The bacteria were isolated and purified using basic microbiological culturing. Characterisation was done based on specific genes present in the bacterial genome. “I amplified these genes with polymerase chain reaction (PCR), using various primers targeting these specific genes,” Dr Strydom said. Some amplification results were analysed with a subsequent restriction digestion where the genes were cut in specific areas with enzymes to create fragments. The lengths of these fragments can be used to differentiate between strains. “I also compared the whole genomes of some of the bacterial strains.” The bacteriophages were then isolated from waste water samples at the facility using the isolated bacterial strains. “However, I was not able to isolate a bacteriophage that could infect the bacteria in the facility.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept